Clinical trials: Prostate Cancer Metastatic Castration-Resistant
Prostate Cancer Metastatic Castration-Resistant, Prostate Cancer
Liquid Biopsy Under PSMA Radioligand Therapy
Prostate cancer is the second most common cause of cancer death in men worldwide. After exhausting guideline-compliant therapies or in accordance with the approval of 177Lu-PSMA-617 (Pluvicto®), patients with metastatic…
- Trial name
- LOOPS (NCT07118436)
- Where
- 3 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Wuerzburg University Hospital
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06145633
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Castration-Resistant Prostate Cancer
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
The purpose of this study was to explore the safety and tolerability of enzalutamide in combination with abiraterone acetate plus prednisone.
- Trial name
- NCT01650194
- Testing
- enzalutamide, abiraterone acetate, prednisone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Castration Resistant Prostate Cancer (mCRPC)
The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
The role of WB-MRI in the evaluation of prostate cancer patients treated with Lu-PSMA
- Trial name
- WB-LuPSMA (NCT05208229)
- Testing
- WB-MRI
- Where
- 2 sites in Italy
- Volunteers
- 2 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Cancer, Castration-resistant Prostate Cancer
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and…
- Conditions
- Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
- Trial name
- ASPIRE-PCa (NCT02066961)
- Where
- 93 sites in Algeria, Argentina and 25 more
- Volunteers
- 1,533 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostate Cancer
A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
The purpose of this study is to learn about the safety of TALZENNA in patients with BRCA mutation-positive metastatic castration-resistant prostate cancer. BRCA mutation positive means any changes to the BRCA gene.
- Trial name
- NCT06733337
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Metastatic Castration-Resistant Prostate Cancer
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to investigate radiographic progression-free survival (PFS) of enzalutamide in chemotherapy-naïve patients with progressive metastatic castration-resistant prostate cancer who have symptomatic disease.
- Trial name
- NCT01663415
- Testing
- Enzalutamide
- Sponsor
- Astellas Pharma Global Development, Inc.
Prostatic Neoplasms, Castration-Resistant
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
This study is a Japanese post-marketing surveillance (PMS) which is required by the regulatory authorities. General objective of PMS is to confirm the clinical usefulness, especially the safety profile of a drug under the routine…
- Trial name
- NCT02803437
- Testing
- Radium-223 dichloride (Xofigo, BAY 88-8223)
- Where
- Japan
- Volunteers
- 334 people
- Sponsor
- Bayer
Metastatic Prostate Carcinoma
Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients
The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223…
- Trial name
- NCT03011749
- Testing
- FLT PET/CT
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet